SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPDR S&P 500 ETF is surging as comments from Donald Trump about the Iran conflict being "very complete, pretty much" trigger a broad market rebound, though many in the community are highly skeptical, calling it a "Trump pump" or "manipulation" and questioning the true de-escalation given ongoing geopolitical tensions. The rapid turnaround has sparked intense debate over the market's current volatility and underlying catalysts.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is highly volatile amid escalating Middle East tensions threatening global oil supply, while conflicting statements from former President Trump suggesting the conflict is "very complete" are causing sharp, contentious reversals. The market remains deeply divided on whether sustained geopolitical risks will outweigh potential de-escalation and strategic reserve releases.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending after reporting strong quarterly results driven by significant MIPLYFFA revenue, which exceeded expectations and signals a commercial breakthrough, fueling community discussions around future profitability, anticipated European approval, and the impact of a new CFO hire.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is surging, fueling a significant short squeeze, after reports of President Trump's optimistic statements suggested the Iran war is 'very complete, pretty much,' leading to a market rebound and a sharp drop in oil prices amid divided investor sentiment.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as escalating geopolitical tensions, particularly concerning a potential conflict involving Iran and its impact on rising oil prices, are driving widespread market fear and discussions of increased volatility. The community is actively debating whether to accumulate UVIX as a hedge against a market correction or if these events are already priced into the market amid perceived manipulation.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy (IMSR) is gaining attention following a new DOE agreement for its IMSR Fuel Salt production pilot and recent positive analyst coverage with a $15 price target. The community actively discusses its Integral Molten Salt Reactor technology as a "dark horse" in the advanced nuclear sector, comparing its potential to peers like OKLO, especially given its strategic position to meet escalating AI data center energy demands.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as bullish investors highly anticipate imminent positive Phase 3 trial results for its AML immunotherapy, GPS, following the CEO's remarks hinting at "curative outcomes" and fueling intense speculation about a potential short squeeze and acquisition interest from major pharmaceutical companies.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Relmada Therapeutics Inc

Relmada Therapeutics is trending following positive 12-month Phase 2 interim data for its bladder cancer candidate NDV-01, which supports advancing to Phase 3, alongside an oversubscribed $160 million private placement financing. The community is vigorously discussing the biotech's significant price and volume surge, anticipating continued momentum for its promising clinical pipeline.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending as it begins early U.S. operations under a White House-backed eVTOL Integration Pilot Program and launches Uber Air in Dubai, marking significant progress toward commercial air taxi services. The community is actively discussing these milestones alongside recent positive earnings and ongoing comparisons with competitor Archer Aviation.

Hewlett Packard Enterprise Co. is a global edge-to-cloud company, which engages in the provision of information technology, technology and enterprise products, solutions, and services. It operates through the following segments: Server, Hybrid Cloud, Intelligent Edge, Financial Services, and Corporate Investments and Other. The Server segment consists of general-purpose servers for multi-workload computing and workload-optimized servers to deliver the performance and value for demanding applications, and integrated systems comprised of software and hardware designed to address high-performance computing and supercomputing, artificial intelligence, data analytics, and transaction processing workloads for government and commercial customers globally. The Hybrid Cloud segment is involved in a variety of cloud-native and hybrid solutions across storage, private cloud, and the infrastructure software-as-a-service space. The Intelligent Edge segment offers wired and wireless local area networks, campus, branch, and data center switching, software-defined wide-area-networks, private and public cellular network software, network security, and associated services that enable secure connectivity for businesses of any size. The Financial Services segment provides investment solutions, such as leasing, financing, IT consumption, utility programs, and asset management services for customers that facilitate technology deployment models and the acquisition of complete IT solutions, including hardware, software, and services from Hewlett Packard Enterprise and others. The Corporate Investments and Other segment includes the Advisory and Professional Services business, which primarily offers consultative-led services, HPE and partner technology expertise and advice, implementation services, as well as complex solution engagement capabilities, the Communications and Media Solutions business, which primarily offers software and related services to the telecommunications industry, and Hewlett Packard Labs, which is responsible for research and development. The company was founded by William R. Hewlett and David Packard on July 2, 1939 and is headquartered in Spring, TX.

Hewlett Packard Enterprise Co

HPE is trending as its recent earnings showcased strong demand for AI systems and significant growth in its networking segment, boosted by the completed Juniper Networks acquisition. The community is actively discussing the company's strategic shift to an AI-driven hybrid cloud and networking powerhouse, anticipating substantial market share gains despite lingering concerns about short-term outlooks and rising component costs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Galapagos Q4 Earnings Call Highlights

Galapagos (NASDAQ:GLPG) executives used the company's year-end 2025 financial results call to outline a strategic reset centered on business development, following a decision to wind down its cell...

Galapagos (NASDAQ:GLPG) Shares Gap Up Following Earnings Beat

Galapagos (NASDAQ:GLPG) Shares Gap Up Following Better-Than-Expected Earnings...

<ul class="summary-bullets"><li>The winding down of the said activities will impact about 365 employees across regions including Europe, the U.S. and China, the company said.&nbsp;</li><li>It will also result in the shut down of sites in the Netherlands, Switzerland, U.S. and China.</li><li>Galapagos CFO Aaron Cox had said in November that the company expects to be cash flow neutral to positive by the end of 2026 if the wind down is implemented.</li></ul> Galapagos NV (GLPG) on Monday announced that its Board of Directors has decided to initiate the wind-down of the company’s cell therapy activities, sending shares up 6% in Monday’s after hours trading.The company had announced its intent to wind down the activities after a strategic review and sale process in October but had held on acting on it until it completed communicating with work councils in the Belgium and Netherlands. The winding down of the said activities will impact about 365 employees across regions including Europe, the U.S. and China, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/05/3213177/0/en/Galapagos-Announces-Board-Decision-to-Initiate-Wind-Down-of-Cell-Therapy-Activities.html">said</a>.It will also result in the shut down of sites in the Netherlands, Switzerland, the U.S. and China. The U.S. facilities to be shut down include one in Princeton and another in Pittsburgh, the company said. More details about the wind down, including details pertaining to its timeline and costs, will be provided with the company’s full year earnings in February, it added.Galapagos CFO Aaron Cox had said in November that the company expects to be cash flow neutral to positive by the end of 2026 if the wind down is implemented.<h2 class="st-heading-2">Future After Wind Down</h2>On Monday, Galapagos said that the wind-down of the cell therapy activities will position it for longer-term growth. The company will continue to manage its non-cell therapy programs and evaluate all strategic alternatives for GLPG3667, an investigational, oral, selective inhibitor of tyrosine kinase 2, to accelerate its development in dermatomyositis and potentially other severe auto-immune indications, the company said.The company will also consider resuming the partnering process for the drug, it said. Galapagos also added that it will continue to maintain its presence at its headquarters in Belgium as well as its hubs in Chicago and San Francisco.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment about GLPG stayed in the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<a href="https://stocktwits.com/symbol/GLPG">GLPG stock</a> has gained 15% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/toyota-us-sales-rise-8-percent-in-q4/cmxMCZPR4Ri">US Heeds Trump To Buy A Toyota: Japanese Automaker’s US Sales Rise 8% In Q4</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A logo of Galapagos, a European pharmaceutical research company, is pictured outside its facility on June 9, 2020 in Leiden, Netherlands. (Photo by Yuriko Nakao/Getty Images) 

Galapagos Stock Rises After Hours On Starting To Wind Down Cell Therapy Activities, Subsequent Workforce Reduction 

The company had announced its intent to wind down the activities after a strategic review and sale process in October.

Equity

The company had announced its intent to wind down the activities after a strategic review and sale process in October.


Galapagos NV (NASDAQ:GLPG) Given Consensus Rating of "Reduce" by Analysts

Galapagos NV (NASDAQ:GLPG - Get Free Report) has been given an average recommendation of "Reduce" by the nine research firms that are presently covering the company, MarketBeat reports. Five equities...

XTX Topco Ltd Makes New $1.11 Million Investment in Galapagos NV $GLPG

XTX Topco Ltd acquired a new stake in Galapagos NV (NASDAQ:GLPG - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired...

Segall Bryant & Hamill LLC Sells 150,384 Shares of Galapagos NV $GLPG

Segall Bryant & Hamill LLC cut its position in shares of Galapagos NV (NASDAQ:GLPG - Free Report) by 23.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the...

Galapagos (NASDAQ:GLPG) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised Galapagos from a "sell" rating to a "hold" rating in a research report on Sunday...

Galapagos (NASDAQ:GLPG) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Galapagos from a "hold" rating to a "sell" rating in a research report on Saturday...

Galapagos NV (NASDAQ:GLPG) Receives Average Rating of "Reduce" from Analysts

Shares of Galapagos NV (NASDAQ:GLPG - Get Free Report) have earned an average recommendation of "Reduce" from the nine analysts that are currently covering the company, Marketbeat.com reports. Six...

Royal Bank Of Canada Issues Positive Forecast for Galapagos (NASDAQ:GLPG) Stock Price

Royal Bank Of Canada boosted their price target on Galapagos from $28.00 to $32.00 and gave the company a "sector perform" rating in a report on Friday...

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Current Price	$33.06
Prev Close	$32.92
Open	$32.59
Dividend Yield	0.00%
50-Day Moving Average	$33.64
Beta	0.51
Avg. Volume	100,899.99
PE Ratio	5.52

52-Week High	$37.78
52-Week Low	$22.59
Market Capitalization	$2.17B
EPS (Annual)	$5.50
Price to Book	0.75
Revenue Per Employee	$1.78M

GLPG
Galapagos

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GLPG News

GLPGGalapagos